Protocol No.: PDS0101-HNC-301

A Phase 3 Open-Label, Randomized Study of PDS0101 Plus Pembrolizumab vs Pembrolizumab Alone in First Line Treatment of Immune Checkpoint Inhibitor (ICI) Naive Subjects with Recurrent and/or Metastatic (R/M) Human Papillomavirus 16 (HPV16)-Positive Head and Neck Squamous Cell Carcinoma (HNSCC))
Principal Investigator
Najeeb, Sidra
Phase
III
Age Group
Adult
Applicable Disease Site
Head and Neck Cancers
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Nina Moore, RN
Research Specialist
Phone: +1 304-293-2991

View on ClinicalTrials.gov